Blog
RSS FeedPosted by Michael Wonder on 22 Apr 2021
New Brunswick becomes third province in Canada to implement biosimilar switching policy
21 April 2021 - Biosimilars Canada today congratulated the Government of New Brunswick for implementing a biosimilar "switching" or transitioning ...
Posted by Michael Wonder on 29 Mar 2021
B.C. woman petitions province to cover cost of 'life-changing' migraine medication
29 March 2021 - Christina Sall says Aimovig is the only drug that helps her, but it costs her more than ...
Posted by Michael Wonder on 25 Mar 2021
High cost patented drugs now account for 50% of sales
25 March 2021 - Federal Minister of Health tables the 2019 Annual Report of the Patented Medicine Prices Review Board ...
Posted by Michael Wonder on 19 Mar 2021
Cystic fibrosis patients call on Premier Ford to provide immediate access to life saving treatments
18 March 2021 - Ontarians with cystic fibrosis made an emotional plea to Premier Ford this week in a video that ...
Posted by Michael Wonder on 04 Mar 2021
Ofev (nintedanib) receives positive recommendation from CADTH and INESSS for the treatment of progressive fibrosing interstitial lung diseases
4 March 2021 - Ofev is the first treatment available in Canada for chronic fibrosing interstitial lung diseases with a progressive ...
Posted by Michael Wonder on 25 Feb 2021
AbbVie’s Skyrizi for the treatment of moderate to severe plaque psoriasis now publicly reimbursed across Canada
24 February 2021 - Prince Edward Island lists Skyrizi on its Pharmacare Formulary effective 22 February 2021. ...
Posted by Michael Wonder on 21 Feb 2021
Ontario makes commitment to funding CF drugs after approval process completed
19 February 2021 - Ontario’s Health Minister Christine Elliott says life-saving cystic fibrosis medications that are inching their way through ...
Posted by Michael Wonder on 18 Feb 2021
Fresenius Kabi Canada launches Idacio (adalimumab injection) a biosimilar to Humira (adalimumab) for the treatment of multiple chronic inflammatory conditions
18 February 2021 - Biosimilars offer patients access to affordable, meaningful medicines ...
Posted by Michael Wonder on 18 Feb 2021
HLS Therapeutics provides update on private and public payer reimbursement for Vascepa
16 February 2021 - Active negotiations have also begun with the pan-Canadian Pharmaceutical Alliance for reimbursement of Vascepa by publicly funded ...
Posted by Michael Wonder on 11 Feb 2021
An institutional ethnographic analysis of public and patient engagement activities at a national health technology assessment agency
9 February 2021 - The practice of public and patient engagement in health technology assessment has spread worldwide, yet gaps in ...
Posted by Michael Wonder on 11 Feb 2021
Cystic fibrosis advocate asks P.E.I. to fast-track coverage of new 'mind-blowing' drug
10 February 2021 - ‘It’s the closest thing we’ve ever had to a cure’. ...
Posted by Michael Wonder on 10 Feb 2021
New drugs entering Canada at steady rate over past 5 years - Canada still among top 10 OECD countries in terms of access to new drugs
10 February 2021 - The latest edition of the Patented Medicine Prices Review Board Meds Entry Watch reports that 40 new-to-Canada ...
Posted by Michael Wonder on 07 Feb 2021
Patient and public involvement in health technology assessment: update of a systematic review of international experiences
5 February 2021 - This paper summarises the current evidence on patient and public involvement in health technology assessment in order ...
Posted by Michael Wonder on 24 Jan 2021
Canada’s drug makers rattle their sabers over a government plan to control medicine spending
21 January 2021 - A majority of pharmaceutical executives in Canada say new regulations designed to cut prescription drug spending ...
Posted by Michael Wonder on 21 Jan 2021
Industry pooling helps maintain affordability of high cost drugs despite significant inflationary pressures
21 January 2021 - In 2019, the Canadian Drug Insurance Pooling Corporation's (CDIPC) high-cost drug sharing framework provided coverage to ...